Astellas Launches Irritable Bowel Syndrome Drug Irribow
This article was originally published in PharmAsia News
Astellas launched Irribow (ramosetron) Oct. 7 in Japan, a drug indicated to treat diarrhea-predominant irritable bowel syndrome in males. A serotonin 5-HT3 receptor antagonist, Irribow is the first serotonin receptor antagonist treatment in Japan. (Click here for more - Japanese language
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.